Predicate |
Object |
assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3b7edd3693b55c0fd41df267c299f173 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_09bd9b29160d3ade2928e67da93e8ee9 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_78587acbfc8d4c9e9ac3baa7021087d7 http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_3da168962c8dbb03e022f08e6ec72ac7 |
classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-14 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-111 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-315 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2310-17 |
classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-1138 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P43-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-04 |
classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-117 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-113 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K48-00 |
filingDate |
2006-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_272f0a53aea6a707ea2ff23ac70ef087 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_66fff65e08f09ed669a58de2594b56eb http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_72365b8b9d1286141231e7d24231f3e3 |
publicationDate |
2006-09-21-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
publicationNumber |
WO-2006099021-A2 |
titleOfInvention |
Direct reversal of the suppressive function of cd4+ regulatory t cells via toll-like receptor 8 signaling |
abstract |
CD4+ regulatory T (Treg) cells profoundly suppress host immune responses and thus protect against autoimmune disease while restricting desired immune responses such as antitumor immunity. Synthetic phosphorothioate-protected, guanosine-containing oligonucleotides can directly reverse the suppressive activity of Treg cells without involving dendritic cells. This effect appears to be transduced by signaling through Toll-like receptor (TLR) 8 and engagement of the MyD88 and IRAK4 molecules in Treg cells. Stimulation of Treg cells with natural ligands for human TLR8 recapitulated the effect of the synthetic guanosine-containing oligonucleotides . |
isCitedBy |
http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2016199544-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/JP-2011529171-A |
priorityDate |
2005-03-09-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
type |
http://data.epo.org/linked-data/def/patent/Publication |